SVF
Level D· Preclinical EvidenceAnimal Study

Injectable and pH-Activated Self-Feedback Hydrogel Encapsulating Stem Cells for Augmented Acute Myocardial Infarction Therapy.

Kong Y., Wang L., Duan F., Huang C., Qiu Z., Ji RJ.

Animal Study on Cardiovascular Disease, published in Adv Healthc Mater (2026) — summary generated from the PubMed abstract.

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Adv Healthc Mater (2026)
Country
Germany
Reported sample size
—
PMID
41131831
DOI
10.1002/adhm.202503324

Abstract (original English)

Hydrogels encapsulating stem cells represent a promising strategy for enhancing cardiac function following acute myocardial infarction (AMI). However, hostile post-infarct microenvironments, characterized by oxidative stress and ischemia, significantly reduce stem cell retention and survival rates. Herein, an intramyocardially injectable and pH-responsive (2' Z, 3' E)-6-Bromoindirubin-3'-oxime (BIO)-N-adipose-derived stem cells (ADSCs)-Matrigel system is developed for treating AMI. Encapsulated ADSCs exhibited a high retention rate in myocardial tissue. Furthermore, BIO-N exhibited a self-feedback function, enabling it to modulate the release of BIO in response to pH changes in the microenvironment during the progression of AMI. This system effectively protected stem cells and cardiomyocytes from ROS-induced injury while enhancing the therapeutic efficacy of ADSCs by improving their paracrine function. Subsequently, it is demonstrated that the BIO-N-ADSCs-Matrigel system significantly reduced infarction size, mitigated fibrosis, and enhanced local angiogenesis in a rat model of AMI. The self-feedback functional BIO-N-ADSCs-Matrigel system can effectively mitigate local oxidative stress, enhance the survival rate and therapeutic efficacy of stem cells, and improve the viability of cardiomyocytes for AMI treatment.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence comes from animal or laboratory studies and has not been confirmed in humans.

How we grade evidence
Myocardial InfarctionAnimalsHydrogelsHydrogen-Ion ConcentrationRatsStem CellsRats, Sprague-DawleyMyocytes, CardiacMaleStem Cell Transplantation
Systemic / IVCardiovascular Disease
View on PubMedDOI

Related research